LEIDEN, the Netherlands, October 30, 2019 / B3C newswire / -- SeraNovo B.V. today announced that it has signed a License Agreement with Carna Biosciences, Inc., a company engaged in drug development specializing in the development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly continue to develop an oral formulation with increased bioavailability. Utilizing its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on constituents that are GRAS for oral administration or broadly used in the industry. The final formulation includes an optimized combination of a DES, one or more polymeric precipitation inhibitors and Carna’s Kinase inhibitor.
Niall Hodgins, Chief Executive Officer of SeraNovo commented: “We are very excited that we have set up this important partnership with Carna Biosciences. We are confident this is just the first step in a long and fruitful partnership with an industry leader. As a start-up company, this partnership represents excellent validation for our breakthrough formulation technology."
SeraNovo is an innovative start-up company engaged in the formulation of active ingredients for oral administration. They focus on solving the problem of poor drug solubility by designing liquid formulations specifically to increase the bioavailability when orally administered. For each of these poorly soluble API’s they design a DES-based formulation which is proven to significantly increase the oral bioavailability. SeraNovo is a privately-owned company located in Leiden, The Netherlands and as technology inventor owns all know-how and IP.
About Carna Biosciences
Carna Biosciences is a biopharmaceutical company focused on the discovery and development of kinase inhibitor drugs to treat serious unmet medical needs in oncology, autoimmune and neurological diseases by inhibiting kinases that are important drivers for those diseases. Carna Biosciences was founded in Kobe, Japan, in 2003 as a spinoff of Japan Organon (Nippon Organon KK). Carna’s initial focus was to develop an extensive number of state-of-the-art, highest quality reagents for kinase drug discovery, and has since established a leading drug discovery program with a significant collection of proprietary chemical libraries.
Forward-Looking Statements: This press release contains "forward-looking statements", including but not limited to statements regarding development plans, the DES Formulation Platform, and product candidates and related capabilities. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from current expectations and projections. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required by law.
Keywords: Biological Availability; Administration, Oral; Pharmaceutical Preparations; Polymers; Solvents; Kinase inhibitor; Deep Eutectic Solvent; DES; GRAS; Formulation;
Published by B3C newswire and shared through Newronic®